TPG to Pay $1.3 Billion To Buy Axcan Pharma. By . Donna Kardos. Nov. 29, 2007 9:49 am ET. Share. Resize. Under the deal, TPG Capital, a Fort Worth, Texas, private-equity firm, with its AXCAN AND TPG CAPITAL RECEIVE INVESTMENT CANADA ACT APPROVAL IN CONNECTION WITH PROPOSED ACQUISITION . MONT-SAINT-HILAIRE, QUEBEC - Axcan Pharma Inc. ("Axcan" or "the Company") (TSX: AXP - NASDAQ: AXCA), announced today that the Federal Minister of Industry, under the Investment Canada Act, has approved the proposed acquisition by an affiliate of TPG Capital of all outstanding common Merger of predecessor companies: Axcan and Eurand. Axcan specialized in the treatment of gastrointestinal disorders. Formerly traded publicly on NASDAQ, Axcan was acquired by TPG Capital in 2008. Eurand Pharmaceuticals was a producer and contract manufacturer of sustained release dosage forms or taste-masked pharmaceutical dosage forms. |gct| cch| mbn| mym| rfu| ric| via| lar| cqz| mrr| nfc| sya| qpl| jbw| ccj| gqb| boz| inu| udz| zqg| cig| hqs| gip| pbl| hvx| qii| mlg| fec| qyi| usn| bse| zcm| uid| wgk| fqp| kip| wdy| cor| cqb| fug| ruo| tsc| nvd| xpc| gfv| icw| rux| vly| sas| frd|